Literature DB >> 27499770

Maspin Gene Expression in Invasive Ductal Carcinoma of Breast.

Shahriar Dabiri1, Mohammadmehdi Moeini Aghtaei1, Jahanbano Shahryari1, Manzume Shamis Meymandi2, Sahar Amirpour-Rostami3, Reza Foutohi Ardekani4.   

Abstract

BACKGROUND: The breast cancer is the most prevalent cancer among women, on the other hand absence of myoepithelial cells play a pivotal role in pathogenesis of this cancer. Thus we aimed to investigate the possible abilities of the molecular assay technique to find a relationship between mammary serine protease inhibitor (Maspin) gene expression possibly secreted by myoepithelial cells, grade of breast cancer and other prognostics factors (ER, PR, and c-erb-B2).
METHODS: Paraffin embedded blocks of 31 breast cancer patients together with two normal breast tissues were used for IHC staining and Maspin gene RNA detection uses the real-time PCR method. Applying QIAGEN kit, we were able to measure Maspin RNA and Extract the cDNA of different samples for evaluating the Maspin RNA level.
RESULTS: We found that the RNA level was considerably lowerin these cancer samples compared with normal samples. In addition, different grades of breast cancer in the obtained results adopt some distinguishable values. The Maspin expression in samples with grades II and III is much lower than the ones in normal group (P<0.05) which could be considered as a promising way in diagnosing of this disease. The results showed no considerable differences in Maspin gene expression of the c-erb-B2 scores in the tumor group except the samples having score 0. The other observation of this research study confirmed that Maspin gene expression couldn't show any differences between the values of both ER and PR in different scores of the tumor group. On the other hand, the cDNA of these patients showed lower values compared with normal samples.
CONCLUSION: Maspin expression was reduced in samples with grade II&amp; III of invasive ductal carcinoma. Based on expression of Maspin Inc-erb-B2, it seems that more expression happened in normal group comparing with different scores of it. We could suggest that there was a reverse relationship between tumor formation and Maspin gene expression. These results showed possible role of Maspin as prognostic factor.

Entities:  

Keywords:  Breast cancer; IRAN; Maspin gene; Prognostic factor; Real-time PCR

Year:  2016        PMID: 27499770      PMCID: PMC4939639     

Source DB:  PubMed          Journal:  Iran J Pathol        ISSN: 1735-5303


  32 in total

1.  Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease.

Authors:  Helen M Heneghan; Nicola Miller; Ronan Kelly; John Newell; Michael J Kerin
Journal:  Oncologist       Date:  2010-06-24

2.  Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

Authors:  Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

Review 3.  Breast cancer statistics, 2011.

Authors:  Carol DeSantis; Rebecca Siegel; Priti Bandi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-10-03       Impact factor: 508.702

4.  Clinicopathological significance of maspin expression in breast cancer.

Authors:  Mi Ja Lee; Chae Hong Suh; Zhu-Hu Li
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

5.  Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells.

Authors:  Valerie A Odero-Marah; Zhila Khalkhali-Ellis; Jirapat Chunthapong; Sumaira Amir; Richard E B Seftor; Elisabeth A Seftor; Mary J C Hendrix
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

6.  Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen.

Authors:  Zhila Khalkhali-Ellis; Abby L Christian; Dawn A Kirschmann; Elijah M Edwards; Maryam Rezaie-Thompson; Mohammad A Vasef; Lynn M Gruman; Richard E B Seftor; Laura E Norwood; Mary J C Hendrix
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

7.  Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer.

Authors:  D H Kim; D S Yoon; W C Dooley; E S Nam; J W Ryu; K C Jung; H R Park; J H Sohn; H S Shin; Y E Park
Journal:  Histopathology       Date:  2003-01       Impact factor: 5.087

8.  Maspin expression in the invasive margin of primary melanomas may reflect an aggressive tumor phenotype.

Authors:  Claudia Pföhler; Tobias Knöpflen; Rebecca Körner; Thomas Vogt; Alexander Rösch; Cornelia S L Müller
Journal:  J Dtsch Dermatol Ges       Date:  2013-07-15       Impact factor: 5.584

9.  Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.

Authors:  E Karlsson; K Sandelin; J Appelgren; W Zhou; K Jirström; J Bergh; F Wärnberg
Journal:  Eur J Cancer       Date:  2013-11-22       Impact factor: 9.162

10.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07
View more
  2 in total

Review 1.  Risk Factors and Preventions of Breast Cancer.

Authors:  Yi-Sheng Sun; Zhao Zhao; Zhang-Nv Yang; Fang Xu; Hang-Jing Lu; Zhi-Yong Zhu; Wen Shi; Jianmin Jiang; Ping-Ping Yao; Han-Ping Zhu
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

2.  The roles of maspin expression in gastric cancer: a meta- and bioinformatics analysis.

Authors:  Hua-Chuan Zheng; Bao-Cheng Gong
Journal:  Oncotarget       Date:  2017-08-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.